Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human F13A1 Protein, Myc/DDK-tagged, C13 and N15-labeled

Cat.No. : F13A1-1890H
Product Overview : F13A1 MS Standard C13 and N15-labeled recombinant protein (NP_000120) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.
  • Specification
  • Gene Information
  • Related Products
Description : This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.
Source : HEK293
Species : Human
Tag : Myc/DDK
Molecular Mass : 83.3 kDa
AA Sequence : MSETSRTAFGGRRAVPPNNSNAAED DLPTVELQGVVPRGVNLQEFLNVTS VHLFKERWDTNKVDHHTDKYENNKL IVRRGQSFYVQIDFSRPYDPRRDLF RVEYVIGRYPQENKGTYIPVPIVSE LQSGKWGAKIVMREDRSVRLSIQSS PKCIVGKFRMYVAVWTPYGVLRTSR NPETDTYILFNPWCEDDAVYLDNEK EREEYVLNDIGVIFYGEVNDIKTRS WSYGQFEDGILDTCLYVMDRAQMDL SGRGNPIKVSRVGSAMVNAKDDEGV LVGSWDNIYAYGVPPSAWTGSVDIL LEYRSSENPVRYGQCWVFAGVFNTF LRCLGIPARIVTNYFSAHDNDANLQ MDIFLEEDGNVNSKLTKDSVWNYHC WNEAWMTRPDLPVGFGGWQAVDSTP QENSDGMYRCGPASVQAIKHGHVCF QFDAPFVFAEVNSDLIYITAKKDGT HVVENVDATHIGKLIVTKQIGGDGM MDITDTYKFQEGQEEERLALETALM YGAKKPLNTEGVMKSRSNVDMDFEV ENAVLGKDFKLSITFRNNSHNRYTI TAYLSANITFYTGVPKAEFKKETFD VTLEPLSFKKEAVLIQAGEYMGQLL EQASLHFFVTARINETRDVLAKQKS TVLTIPEIIIKVRGTQVVGSDMTVI VEFTNPLKETLRNVWVHLDGPGVTR PMKKMFREIRPNSTVQWEEVCRPWV SGHRKLIASMSSDSLRHVYGELDVQ IQRRPSMTRTRPLEQKLISEEDLAA NDILDYKDDDDKV
Purity : > 80% as determined by SDS-PAGE and Coomassie blue staining
Stability : Stable for 3 months from receipt of products under proper storage and handling conditions.
Storage : Store at -80 centigrade. Avoid repeated freeze-thaw cycles.
Concentration : 50 μg/mL as determined by BCA
Storage Buffer : 100 mM glycine, 25 mM Tris-HCl, pH 7.3.
Gene Name : F13A1 coagulation factor XIII A chain [ Homo sapiens (human) ]
Official Symbol : F13A1
Synonyms : F13A1; coagulation factor XIII, A1 polypeptide; F13A; coagulation factor XIII A chain; TGase; factor XIIIa; fibrinoligase; FSF, A subunit; coagulation factor XIIIa; transglutaminase A chain; transglutaminase. plasma; fibrin stabilizing factor, A subunit; coagulation factor XIII, A polypeptide; protein-glutamine gamma-glutamyltransferase A chain; bA525O21.1 (coagulation factor XIII, A1 polypeptide);
Gene ID : 2162
mRNA Refseq : NM_000129
Protein Refseq : NP_000120
MIM : 134570
UniProt ID : P00488

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
How does F13A1 contribute to the stability of fibrin clots? 11/16/2021

F13A1 crosslinks fibrin chains, enhancing the stability and resistance of fibrin clots to breakdown.

Are there any genetic factors linked to F13A1 deficiency? 03/20/2021

Yes, F13A1 deficiency can be inherited, with autosomal recessive inheritance being the most common pattern.

What are the potential therapeutic interventions for F13A1 deficiency? 06/05/2020

Treatment may involve F13A1 replacement therapy or transfusions of plasma rich in F13A1.

Is F13A1 protein used as a biomarker in any clinical conditions? 12/20/2019

F13A1 levels are sometimes used as a biomarker to assess the risk of bleeding or thrombotic events in certain clinical conditions.

Can abnormalities in F13A1 levels be associated with cardiovascular diseases? 06/23/2016

Some studies suggest that altered F13A1 levels may be associated with an increased risk of certain cardiovascular diseases.

Customer Reviews (3)

Write a review
Reviews
06/30/2020

    The protein's unique properties allow researchers to gain insights into the underlying mechanisms and explore potential therapeutic interventions.

    07/24/2018

      They continuously invest in research and development, ensuring that their offerings remain at the forefront of scientific advancements.

      12/01/2016

        With the IGF2R protein and the manufacturer's assistance, my trials have been empowered to yield impactful findings, contributing to advancements in the field of biomedical research.

        Ask a Question for All F13A1 Products

        Required fields are marked with *

        My Review for All F13A1 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends